Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné
Nicolas
N
Department of Radiation Oncology, Institut Gustave-Roussy, Villejuif Cedex, France. nicolas.magne@igr.fr
Chargari
Cyrus
C
D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D019317:Evidence-Based Medicine; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods; D012307:Risk Factors; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab